Bayer AG
XETRA:BAYN

Watchlist Manager
Bayer AG Logo
Bayer AG
XETRA:BAYN
Watchlist
Price: 23.57 EUR 2.93%
Market Cap: 23.2B EUR
Have any thoughts about
Bayer AG?
Write Note
Section:
 

Relative Value

The Relative Value of one BAYN stock under the Base Case scenario is 78.27 EUR. Compared to the current market price of 23.57 EUR, Bayer AG is Undervalued by 70%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BAYN Relative Value
Base Case
78.27 EUR
Undervaluation 70%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.5
P/S
P/S
Price to Sales
0.5
vs History
92
vs Industry
81
Median 3Y
0.9
Median 5Y
1
Industry
2.4
Forward
0.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
40
Median 3Y
9.5
Median 5Y
-4.2
Industry
20.3
Forward
4.6
More Details
2.9
P/OCF
P/OCF
Price to OCF
2.9
vs History
92
vs Industry
47
Median 3Y
7.2
Median 5Y
7.5
Industry
15.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
31
Median 3Y
9.8
Median 5Y
8.1
Industry
22.5
More Details
0.8
P/B
P/B
Price to Book Value
0.8
vs History
90
vs Industry
68
Median 3Y
1.2
Median 5Y
1.3
Industry
2
More Details
1.1
EV/S
EV/S
Enterprise Value to Sales
1.1
vs History
90
vs Industry
67
Median 3Y
1.5
Median 5Y
1.6
Industry
2.5
Forward
1.1
More Details
2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2
vs History
90
vs Industry
70
Median 3Y
2.4
Median 5Y
2.7
Industry
4.8
More Details
5.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5.6
vs History
52
vs Industry
45
Median 3Y
5.8
Median 5Y
5.8
Industry
12.5
Forward
5.1
More Details
26.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
26.8
vs History
7
vs Industry
5
Median 3Y
14.2
Median 5Y
12
Industry
15.5
Forward
9.2
More Details
6.7
EV/OCF
EV/OCF
Enterprise Value to OCF
6.7
vs History
87
vs Industry
39
Median 3Y
10.8
Median 5Y
11.5
Industry
13.9
More Details
10
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
10
vs History
73
vs Industry
24
Median 3Y
16.6
Median 5Y
17.4
Industry
17.7
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
79
vs Industry
74
Median 3Y
0.7
Median 5Y
0.7
Industry
1.7
More Details

Multiples Across Competitors

BAYN Competitors Multiples
Bayer AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
Bayer AG
XETRA:BAYN
22.9B EUR 0.5 -26.3 5.6 26.8
US
Eli Lilly and Co
NYSE:LLY
759.6B USD 16.9 71.7 41.7 46.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
392.3B USD 4.4 27.9 13.1 17.1
DK
Novo Nordisk A/S
CSE:NOVO B
2.4T DKK 8.2 23.5 15.4 17.5
CH
Roche Holding AG
SIX:ROG
241.2B CHF 4.1 21 11.7 13.9
US
Merck & Co Inc
NYSE:MRK
239.8B USD 3.7 14 9.4 11.1
UK
AstraZeneca PLC
LSE:AZN
184.1B GBP 4.4 33.9 127.4 194.6
CH
Novartis AG
SIX:NOVN
194.7B CHF 4.3 18.5 11.2 14.3
IE
Endo International PLC
LSE:0Y5F
158.2B USD 68.2 -54.1 253.2 634.9
US
Pfizer Inc
NYSE:PFE
145B USD 2.3 18.1 8.6 12.3
P/E Multiple
Earnings Growth PEG
DE
Bayer AG
XETRA:BAYN
Average P/E: 28.6
Negative Multiple: -26.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
71.7
48%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.9
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
23.5
19%
1.2
CH
Roche Holding AG
SIX:ROG
21
16%
1.3
US
Merck & Co Inc
NYSE:MRK
14
17%
0.8
UK
AstraZeneca PLC
LSE:AZN
33.9
36%
0.9
CH
Novartis AG
SIX:NOVN
18.5
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -54.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.1
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DE
Bayer AG
XETRA:BAYN
Average EV/EBITDA: 394.9
5.6
-17%
N/A
US
Eli Lilly and Co
NYSE:LLY
41.7
29%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.4
11%
1.4
CH
Roche Holding AG
SIX:ROG
11.7
7%
1.7
US
Merck & Co Inc
NYSE:MRK
9.4
11%
0.9
UK
AstraZeneca PLC
LSE:AZN
127.4
8%
15.9
CH
Novartis AG
SIX:NOVN
11.2
4%
2.8
IE
E
Endo International PLC
LSE:0Y5F
253.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.6
2%
4.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DE
Bayer AG
XETRA:BAYN
Average EV/EBIT: 1 699.2
26.8
-8%
N/A
US
Eli Lilly and Co
NYSE:LLY
46.1
31%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.1
11%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.5
16%
1.1
CH
Roche Holding AG
SIX:ROG
13.9
9%
1.5
US
Merck & Co Inc
NYSE:MRK
11.1
12%
0.9
UK
AstraZeneca PLC
LSE:AZN
194.6
19%
10.2
CH
Novartis AG
SIX:NOVN
14.3
9%
1.6
IE
E
Endo International PLC
LSE:0Y5F
634.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.3
10%
1.2

See Also

Summary
BAYN intrinsic value, competitors valuation, and company profile.
DCF Valuation
BAYN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BAYN stock valuation using valuation multiples.
Wall Street Estimates
BAYN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BAYN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 238,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.